Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Vericel Corporation VCEL

Healthcare  —  Biotechnology
39.71 0.41 1.04% as of 25 Sep
Market cap
$2.0B
P/E
82.6×
Revenue Champion (10y)
Growth Flags show if company had growth for consecutive years
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Vericel Corporation (VCEL) Business Profile

Updated before January 2025

Company Overview

Vericel Corporation (NASDAQ: VCEL) is a leading biotechnology company specializing in advanced cell therapies for the treatment of severe diseases and conditions. Founded in 1989 and headquartered in Cambridge, Massachusetts, Vericel has established itself as a pioneer in regenerative medicine. The company focuses on developing and commercializing innovative therapies that leverage the body’s own cells to repair or regenerate damaged tissues.

The company’s leadership team is composed of experienced professionals in the biotechnology and healthcare industries. Dominating the helm is CEO Dominick Colangelo, who has been instrumental in driving the company’s growth and strategic direction. Under his leadership, Vericel has expanded its product portfolio and strengthened its position in the regenerative medicine market.

Core Business Segments

Vericel Corporation operates in two primary business segments: Advanced Cell Therapies and Specialty Biologics. These segments are supported by a robust portfolio of FDA-approved products and innovative solutions.

Advanced Cell Therapies

  1. MACI® (Matrix-Induced Autologous Chondrocyte Implantation):

    • MACI is a leading product for the treatment of cartilage defects in the knee. It uses a patient’s own cells to repair damaged cartilage, offering a minimally invasive and effective solution for patients suffering from knee pain and mobility issues.

  2. Epicel®:

    • Epicel is a permanent skin replacement therapy for patients with severe burns covering more than 30% of their total body surface area. It is a life-saving treatment that uses the patient’s own skin cells to create grafts for burn wound coverage.

Specialty Biologics

  1. NexoBrid®:
    • NexoBrid is an enzymatic debridement agent used to remove dead or damaged tissue from burn wounds. It provides a non-surgical alternative for burn care, reducing the need for surgical excision and improving patient outcomes.

Business Model

Vericel’s business model is centered around the development, manufacturing, and commercialization of cell-based therapies. The company integrates its products and services by leveraging its proprietary technologies and expertise in regenerative medicine. Revenue is primarily generated through the sale of its FDA-approved products, including MACI, Epicel, and NexoBrid.

Vericel collaborates with healthcare providers, hospitals, and burn centers to ensure the effective delivery of its therapies. The company also invests heavily in research and development to expand its product pipeline and maintain its competitive edge in the market.

Strategic Direction

Vericel is committed to advancing the field of regenerative medicine and expanding its impact on patient care. The company’s strategic priorities include:

  1. Product Expansion:

    • Vericel aims to broaden its product portfolio by developing new cell-based therapies and exploring additional indications for its existing products.

  2. Geographic Expansion:

    • The company is focused on expanding its presence in international markets to reach a larger patient population.

  3. Sustainability Goals:

    • Vericel is dedicated to sustainable manufacturing practices and reducing its environmental footprint. The company is exploring ways to optimize its production processes and minimize waste.

  4. Innovation:

    • Vericel continues to invest in research and development to drive innovation and maintain its leadership position in the regenerative medicine space.

Competitive Landscape

Vericel operates in a highly competitive market, facing competition from both established players and emerging biotech companies. Key competitors include:

  1. Organogenesis Holdings Inc.:

    • A leading regenerative medicine company specializing in advanced wound care and surgical biologics.

  2. MiMedx Group, Inc.:

    • A biopharmaceutical company focused on placental tissue-based therapies for wound care and musculoskeletal conditions.

  3. Smith & Nephew:

    • A global medical technology company offering a range of products for orthopedics, wound care, and sports medicine.

  4. Avita Medical:

    • A regenerative medicine company specializing in skin restoration therapies.

Risk Factors

Vericel faces several risks that could impact its business operations and financial performance:

  1. Market Dependence:

    • The company relies heavily on the success of its core products, MACI and Epicel. Any decline in demand or competition could adversely affect revenue.

  2. Regulatory Challenges:

    • As a biotechnology company, Vericel is subject to stringent regulatory requirements. Delays or failures in obtaining regulatory approvals could hinder product launches.

  3. Supply Chain Disruptions:

    • The company’s reliance on specialized manufacturing processes and suppliers makes it vulnerable to supply chain disruptions.

  4. Economic Conditions:

    • Economic downturns or changes in healthcare reimbursement policies could impact the affordability and accessibility of Vericel’s therapies.

Recent Developments

  1. NexoBrid Approval:

    • In 2023, Vericel received FDA approval for NexoBrid, further strengthening its position in the burn care market.

  2. Partnerships:

    • The company has entered into strategic partnerships with leading healthcare institutions to enhance the adoption of its therapies.

  3. R&D Investments:

    • Vericel has increased its investment in research and development to accelerate the development of new therapies and expand its product pipeline.

Investment Considerations

Strengths:

  1. Market Leadership:

    • Vericel is a leader in the regenerative medicine space, with a strong portfolio of FDA-approved products.

  2. Innovative Therapies:

    • The company’s focus on cell-based therapies positions it at the forefront of medical innovation.

  3. Growth Potential:

    • Vericel’s strategic initiatives, including product and geographic expansion, offer significant growth opportunities.

Risks:

  1. Regulatory and Market Risks:

    • Dependence on regulatory approvals and market acceptance of its products.

  2. Competition:

    • Intense competition from established players and new entrants in the regenerative medicine market.

Conclusion

Vericel Corporation is a pioneering biotechnology company with a strong focus on regenerative medicine. Its innovative cell-based therapies, including MACI, Epicel, and NexoBrid, have transformed patient care in orthopedics and burn treatment. With a robust growth strategy and commitment to innovation, Vericel is well-positioned to capitalize on the growing demand for regenerative therapies. However, investors should carefully consider the risks associated with regulatory challenges and market competition. Overall, Vericel’s strong market position and growth potential make it a compelling player in the biotechnology industry.